Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.

Isabell Witzel; S Loibl; G von Minckwitz; H Eidtmann; T Fehm; F Khandan; S Schmatloch; M Hauschild; J Bischoff; P A Fasching; C Mau; C Schem; B Rack; I Meinhold-Heerlein; C Liedtke; T Karn; J Huober; Christine Gräfin Zu Eulenburg; Y Issa-Nummer; M Untch; Volkmar Müller

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.

Standard

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial. / Witzel, Isabell; Loibl, S; von Minckwitz, G; Eidtmann, H; Fehm, T; Khandan, F; Schmatloch, S; Hauschild, M; Bischoff, J; Fasching, P A; Mau, C; Schem, C; Rack, B; Meinhold-Heerlein, I; Liedtke, C; Karn, T; Huober, J; Zu Eulenburg, Christine Gräfin; Issa-Nummer, Y; Untch, M; Müller, Volkmar.

In: BRIT J CANCER, Vol. 107, No. 6, 6, 2012, p. 956-960.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Witzel, I, Loibl, S, von Minckwitz, G, Eidtmann, H, Fehm, T, Khandan, F, Schmatloch, S, Hauschild, M, Bischoff, J, Fasching, PA, Mau, C, Schem, C, Rack, B, Meinhold-Heerlein, I, Liedtke, C, Karn, T, Huober, J, Zu Eulenburg, CG, Issa-Nummer, Y, Untch, M & Müller, V 2012, 'Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.', BRIT J CANCER, vol. 107, no. 6, 6, pp. 956-960. <http://www.ncbi.nlm.nih.gov/pubmed/22892393?dopt=Citation>

APA

Witzel, I., Loibl, S., von Minckwitz, G., Eidtmann, H., Fehm, T., Khandan, F., Schmatloch, S., Hauschild, M., Bischoff, J., Fasching, P. A., Mau, C., Schem, C., Rack, B., Meinhold-Heerlein, I., Liedtke, C., Karn, T., Huober, J., Zu Eulenburg, C. G., Issa-Nummer, Y., ... Müller, V. (2012). Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial. BRIT J CANCER, 107(6), 956-960. [6]. http://www.ncbi.nlm.nih.gov/pubmed/22892393?dopt=Citation

Vancouver

Witzel I, Loibl S, von Minckwitz G, Eidtmann H, Fehm T, Khandan F et al. Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial. BRIT J CANCER. 2012;107(6):956-960. 6.

Bibtex

@article{b85b88f9624046a89110f3cbcb18a0b9,

title = "Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.",

abstract = "We were able to demonstrate a predictive value of serum HER2 (sHER2) in patients receiving trastuzumab in the neoadjuvant GeparQuattro trial. However, the role of sHER2 in patients receiving neoadjuvant therapy (NT) with lapatinib is still unclear.",

keywords = "Adult, Humans, Aged, Female, Middle Aged, Multivariate Analysis, Treatment Outcome, Predictive Value of Tests, Enzyme-Linked Immunosorbent Assay, Drug Administration Schedule, Tumor Markers, Biological/*blood, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antineoplastic Agents/administration & dosage/*therapeutic use, Antibodies, Monoclonal, Humanized/administration & dosage/*therapeutic use, Breast Neoplasms/*blood/*drug therapy, *Neoadjuvant Therapy/methods, Quinazolines/administration & dosage/*therapeutic use, Receptor, erbB-2/*blood, Receptors, Estrogen/blood, Translational Medical Research, Adult, Humans, Aged, Female, Middle Aged, Multivariate Analysis, Treatment Outcome, Predictive Value of Tests, Enzyme-Linked Immunosorbent Assay, Drug Administration Schedule, Tumor Markers, Biological/*blood, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antineoplastic Agents/administration & dosage/*therapeutic use, Antibodies, Monoclonal, Humanized/administration & dosage/*therapeutic use, Breast Neoplasms/*blood/*drug therapy, *Neoadjuvant Therapy/methods, Quinazolines/administration & dosage/*therapeutic use, Receptor, erbB-2/*blood, Receptors, Estrogen/blood, Translational Medical Research",

author = "Isabell Witzel and S Loibl and {von Minckwitz}, G and H Eidtmann and T Fehm and F Khandan and S Schmatloch and M Hauschild and J Bischoff and Fasching, {P A} and C Mau and C Schem and B Rack and I Meinhold-Heerlein and C Liedtke and T Karn and J Huober and {Zu Eulenburg}, {Christine Gr{\"a}fin} and Y Issa-Nummer and M Untch and Volkmar M{\"u}ller",

year = "2012",

language = "English",

volume = "107",

pages = "956--960",

journal = "BRIT J CANCER",

issn = "0007-0920",

publisher = "NATURE PUBLISHING GROUP",

number = "6",

}

RIS

TY - JOUR

T1 - Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.

AU - Witzel, Isabell

AU - Loibl, S

AU - von Minckwitz, G

AU - Eidtmann, H

AU - Fehm, T

AU - Khandan, F

AU - Schmatloch, S

AU - Hauschild, M

AU - Bischoff, J

AU - Fasching, P A

AU - Mau, C

AU - Schem, C

AU - Rack, B

AU - Meinhold-Heerlein, I

AU - Liedtke, C

AU - Karn, T

AU - Huober, J

AU - Zu Eulenburg, Christine Gräfin

AU - Issa-Nummer, Y

AU - Untch, M

AU - Müller, Volkmar

PY - 2012

Y1 - 2012

N2 - We were able to demonstrate a predictive value of serum HER2 (sHER2) in patients receiving trastuzumab in the neoadjuvant GeparQuattro trial. However, the role of sHER2 in patients receiving neoadjuvant therapy (NT) with lapatinib is still unclear.

AB - We were able to demonstrate a predictive value of serum HER2 (sHER2) in patients receiving trastuzumab in the neoadjuvant GeparQuattro trial. However, the role of sHER2 in patients receiving neoadjuvant therapy (NT) with lapatinib is still unclear.

KW - Adult

KW - Humans

KW - Aged

KW - Female

KW - Middle Aged

KW - Multivariate Analysis

KW - Treatment Outcome

KW - Predictive Value of Tests

KW - Enzyme-Linked Immunosorbent Assay

KW - Drug Administration Schedule

KW - Tumor Markers, Biological/blood

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Antineoplastic Agents/administration & dosage/therapeutic use

KW - Antibodies, Monoclonal, Humanized/administration & dosage/therapeutic use

KW - Breast Neoplasms/blood/drug therapy

KW - Neoadjuvant Therapy/methods

KW - Quinazolines/administration & dosage/therapeutic use

KW - Receptor, erbB-2/blood

KW - Receptors, Estrogen/blood

KW - Translational Medical Research

KW - Adult

KW - Humans

KW - Aged

KW - Female

KW - Middle Aged

KW - Multivariate Analysis

KW - Treatment Outcome

KW - Predictive Value of Tests

KW - Enzyme-Linked Immunosorbent Assay

KW - Drug Administration Schedule

KW - Tumor Markers, Biological/blood

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Antineoplastic Agents/administration & dosage/therapeutic use

KW - Antibodies, Monoclonal, Humanized/administration & dosage/therapeutic use

KW - Breast Neoplasms/blood/drug therapy

KW - Neoadjuvant Therapy/methods

KW - Quinazolines/administration & dosage/therapeutic use

KW - Receptor, erbB-2/blood

KW - Receptors, Estrogen/blood

KW - Translational Medical Research

M3 - SCORING: Journal article

VL - 107

SP - 956

EP - 960

JO - BRIT J CANCER

JF - BRIT J CANCER

SN - 0007-0920

IS - 6

M1 - 6

ER -